This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Jul 2011

Health Canada Approves New Lupus Drug

For the first time in almost 50 years Canadians living with lupus have a new treatment option.

Health Canada has approved BENLYSTA (belimumab), a new drug specific for the treatment of systemic lupus erythematosus (SLE, or simply lupus). The treatment is expected to become available to patients in Canada in September of this year.


The announcement was made by GlaxoSmithKline and Human Genome Sciences (HGS) who are developing BENLYSTA.


BENLYSTA is indicated for use in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus. The safety and efficacy of BENLYSTA have not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. The efficacy of BENLYSTA in patients of black African heritage has not been clearly establ

Related News